Document Detail


An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
MedLine Citation:
PMID:  19674789     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of < or =30 mg/day. The most common adverse events were diarrhea, hypertension and fatigue. Six patients experienced an objective response (3 each at 20 and 30 mg). Dose- and time-dependent reductions in sVEGFR-2 were observed, and there was a positive correlation between cediranib exposure and the change in plasma VEGF levels from baseline. Cediranib was generally well tolerated and showed preliminary evidence of activity as a monotherapy.
Authors:
Walter Fiedler; Rolf Mesters; Michael Heuser; Gerhard Ehninger; Wolfgang E Berdel; Ute Zirrgiebel; Jane D Robertson; Tom A Puchalski; Barbara Collins; Juliane M Jürgensmeier; Hubert Serve
Related Documents :
8035619 - A case of polycythemia vera occurring in a patient with acute non-lymphoblastic leukemi...
8375859 - Multifocal necrotizing leukoencephalopathy with pontine predilection in immunosuppresse...
15813849 - Del (9q) aml: clinical and cytological characteristics and prognostic implications.
3475159 - Sequential karyotype study on ph-positive chronic myelocytic leukemia. significance of ...
6849839 - Coexistent myelodysplasia and plasma cell neoplasia.
7656199 - Molecular breakpoints of t(11;14)(q13;q32) in multiple myeloma.
1776349 - Extracranial carotid artery aneurysms.
6275499 - Arthralgia and crystal deposits in crohn's disease.
11473749 - Lipid disorders and plaque imaging.
Publication Detail:
Type:  Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2009-08-11
Journal Detail:
Title:  Leukemia research     Volume:  34     ISSN:  1873-5835     ISO Abbreviation:  Leuk. Res.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-01     Completed Date:  2010-03-10     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  196-202     Citation Subset:  IM    
Copyright Information:
Copyright 2009 Elsevier Ltd. All rights reserved.
Affiliation:
Department of Oncology, Hematology, BMT with section Pneumology Hubertus Wald Tumorzentrum - University Cancer Center Hamburg University Medical Center Hamburg Eppendorf 20246 Hamburg, Germany. Fiedler@uke.uni-hamburg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Diarrhea / chemically induced
Fatigue / chemically induced
Female
Humans
Hypertension / chemically induced
Leukemia, Myeloid, Acute / complications,  drug therapy*
Male
Middle Aged
Pilot Projects
Proto-Oncogene Proteins c-kit / drug effects
Quinazolines / administration & dosage*,  adverse effects,  therapeutic use
Signal Transduction / drug effects
Treatment Outcome
Vascular Endothelial Growth Factor Receptor-2 / drug effects
Chemical
Reg. No./Substance:
0/Quinazolines; EC 2.7.10.1/Proto-Oncogene Proteins c-kit; EC 2.7.10.1/Vascular Endothelial Growth Factor Receptor-2; NQU9IPY4K9/cediranib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A placental protective role for trophoblast-derived TNF-related apoptosis-inducing ligand (TRAIL).
Next Document:  Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treate...